-

Savara to Present at the Jefferies London Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

A pre-recorded, on-demand webcast of Savara’s presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the presentation will be available on the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ for 90 days following the event.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Contacts

Savara Inc. IR & PR
Anne Erickson
Senior Vice President, Chief of Staff
anne.erickson@savarapharma.com
(512) 851-1366

Industry:

Savara Inc.

NASDAQ:SVRA
Release Versions
English

Contacts

Savara Inc. IR & PR
Anne Erickson
Senior Vice President, Chief of Staff
anne.erickson@savarapharma.com
(512) 851-1366

More News From Savara Inc.

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the data presented...

Savara Reports First Quarter Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2026 and provided a business update. "With approximately $203 million in cash and, upon MOLBREEVI approval, access to up to an additional $150 million in non-dilutive capital through debt and royalty structures, we remain well capitalized to fund global commercial launch prepa...

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters. The live webcast and subsequent replay will be available on the “Events & Presentations” sectio...
Back to Newsroom